Botanix Pharmaceuticals (ASX:BOT) has announced the promotion of Paul Seaback to Chief Operating Officer, a move the commercial dermatology company said will strengthen day-to-day operations and drive strategic growth across its Philadelphia and Phoenix businesses.
Mr Seaback will oversee the company’s operational functions and lead initiatives to improve efficiencies and cross-functional collaboration.
Mr Seaback joined Botanix in November 2024 as Chief Technical Officer with responsibility for CMC Supply Quality, Regulatory, Pharmacovigilance, Medical Affairs, and Tech Services, and the company credited him with bringing significant operational expertise.
His career spans more than three decades and includes site leadership for drug substance and drug product, as well as corporate oversight of end-to-end supply and business operations. Before Botanix, he was Chief Technical Officer at Dermavant Sciences, where he built the global CMC and technical organisation through its transition from the clinical stage to commercialisation following its acquisition by Organon.
Botanix Chief Executive Officer Dr Howie McKibbon said, “Paul Seaback is a dynamic and results-driven leader who brings deep operational expertise and a strong vision for the future”, and added that the promotion recognises Seaback’s contributions as the company expands capabilities and delivers value to customers and shareholders.
Mr Seaback added, “I’m thrilled to assume this role at such an exciting time for the Company”, and that he looks forward to “working with the talented and dedicated team to build on the company’s strong foundation and help drive the next phase of growth.”